Abstract |
We investigated whether the therapeutic action of sulindac, used for the treatment of familial adenomatous polyposis, desmoid tumors, and against colon cancer, could be mediated by its active metabolite, sulindac sulfide, in cell growth and apoptosis on cell lines derived from abdominal neoplasms. Sulindac sulfide actions on cell growth and apoptosis were evaluated in epithelial human colon tumor 8 (HCT8) cell line and mesenchymal cell lines (bovine bone endothelial (BBE) cell line, desmoid tumor-derived cells, human colorectal cancer-derived fibroblasts). Sulindac sulfide (0.1-60 microg/ml) induced a dose-dependent inhibition of cell proliferation of all cell lines tested. Apoptosis was induced at doses of 20 and 40 microg/ml, respectively, in BBE and HCT8 cells with no effect on desmoid tumor cells and colorectal cancer-derived fibroblasts. Since mesenchymal cells respond to clinically effective concentrations of the compound, its preferential action on the stromal compartment of intestinal polyps, desmoid tumors and colon cancer can be proposed, with consequent regression of the tumor.
|
Authors | L Picariello, M L Brandi, L Formigli, S Z Orlandini, P Dolara, G Caderni, L Raimondi, F Tonelli |
Journal | European journal of pharmacology
(Eur J Pharmacol)
Vol. 360
Issue 1
Pg. 105-12
(Oct 30 1998)
ISSN: 0014-2999 [Print] Netherlands |
PMID | 9845279
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Sulindac
- sulindac sulfide
|
Topics |
- Abdominal Neoplasms
(genetics, pathology)
- Animals
- Antineoplastic Agents
(pharmacology)
- Apoptosis
(drug effects, genetics)
- Cell Division
(drug effects)
- Cell Line
- DNA Fragmentation
(drug effects)
- Dose-Response Relationship, Drug
- Epithelial Cells
(cytology, drug effects)
- Humans
- Mesoderm
(cytology, drug effects)
- Sulindac
(analogs & derivatives, pharmacology)
- Tumor Cells, Cultured
(cytology, drug effects, ultrastructure)
|